The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Charles Stanley Says Accumulate AstraZeneca

Tue, 11th Aug 2015 08:43

LONDON (Alliance News) - The following shares received analyst recommendations Tuesday morning & Monday:
----------
FTSE 100
----------
CITIGROUP REMOVES ARM HOLDINGS FROM 'CITI FOCUS LIST EUROPE' - 'BUY'
----------
CITIGROUP RAISES RANDGOLD RESOURCES PRICE TARGET TO 4745 (4644) PENCE - 'BUY'
----------
JPMORGAN RAISES TRAVIS PERKINS PRICE TARGET TO 2550 (2300) PENCE - 'OVERWEIGHT'
----------
BERENBERG RAISES GLAXOSMITHKLINE PRICE TARGET TO 1575 (1570) PENCE - 'HOLD'
----------
BARCLAYS RAISES RSA INSURANCE PRICE TARGET TO 440 (436) PENCE - 'EQUAL WEIGHT'
----------
S&P CAPITAL IQ CUTS SCHRODERS PRICE TARGET TO 3400 (3500) PENCE - 'HOLD'
----------
S&P CAPITAL IQ RAISES INMARSAT TO 'HOLD' ('SELL') - TARGET 1000 (900) PENCE
----------
CHARLES STANLEY CUTS DIRECT LINE TO 'REDUCE' ('HOLD') - TARGET 330 (328) PENCE
----------
CHARLES STANLEY CUTS AVIVA PRICE TARGET TO 590 (615) PENCE - 'HOLD'
----------
CHARLES STANLEY CUTS HSBC PRICE TARGET TO 640 (650) PENCE - 'HOLD'
----------
CHARLES STANLEY RAISES ASTRAZENECA TO 'ACCUMULATE' ('HOLD')
----------
FTSE 250
----------
NUMIS CUTS LADBROKES PRICE TARGET TO 110 (140) PENCE - 'HOLD'
----------
TRADERS: PEEL HUNT RAISES MONEYSUPERMARKET.COM TO 'BUY' ('HOLD')
----------
NOMURA CUTS WILLIAM HILL PRICE TARGET TO 433 (443) PENCE - 'BUY'
----------
NOMURA RAISES BETFAIR PRICE TARGET TO 2094 (1838) PENCE - 'REDUCE'
----------
JPMORGAN CUTS ESURE GROUP PRICE TARGET TO 295 (299) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RESUMES KIER GROUP WITH 'OVERWEIGHT' - TARGET 1638 PENCE
----------
BARCLAYS CUTS ESURE GROUP PRICE TARGET TO 295 (300) PENCE - 'OVERWEIGHT'
----------
TRADERS: KEPLER CHEUVREUX CUTS ULTRA ELECTRONICS TO 'HOLD' ('BUY')
----------
TRADERS: MORGAN STANLEY CUTS KAZ MINERALS TO 'UNDERWEIGHT' ('EQUAL-WEIGHT')
----------
TRADERS: MORGAN STANLEY RAISES BBA AVIATION TO 'EQUAL-WEIGHT' ('UNDERWEIGHT')
----------
RBC CAPITAL MARKETS RAISES BALFOUR BEATTY TO OUTPERFORM FROM SECTOR PERFORM
----------
MAIN MARKET AND AIM
----------
NUMIS CUTS JOHNSTON PRESS PRICE TARGET TO 115 (168) PENCE - 'HOLD'
----------
NUMIS CUTS ROTALA TO 'HOLD' ('ADD') - TARGET 74 (70) PENCE
----------
PANMURE CUTS PARTNERSHIP ASSURANCE TO 'HOLD' ('BUY') - TARGET 165 (175) PENCE
----------
LIBERUM RESUMES ROCKHOPPER EXPLORATION WITH 'BUY' - TARGET 138 PENCE
----------
Cantor Puts UK Mail Group At Hold From Under Review, Cuts Price Target To 450p From 590p
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.